Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

Moderna is to expand its US manufacturing capabilities with the onshoring of drug product manufacture to its existing Moderna ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

Moderna (MRNA) stock gains as the firm projects 10% growth for next year ahead of the consensus as it plans to conduct the ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Moderna, Inc. (MRNA) on Wednesday announced that it will bring drug product manufacturing to its existing Moderna Technology ...